Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression

Psychiatry Research

Volumn 197, Issue 3, 2012, Pages 221-226

  Weissman, Judith ^a   Flint, Alastair ^b,c,d   Meyers, Barnett ^a   Ghosh, Samiran ^a   Mulsant, Benoit ^b,e,f   Rothschild, Anthony ^g   Whyte, Ellen ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Attrition; Efficacy; Major depressive disorder with psychotic features; Pharmacologic treatment; Randomized controlled trial; Tolerability

Indexed keywords

OLANZAPINE; PLACEBO; SERTRALINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DELUSION; DEPRESSIVE PSYCHOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PLACEBOS; SERTRALINE;

EID: 84865069746     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.02.015     Document Type: Article

References (24)

1. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000, 157:1-45. (Suppl.).
2. Andreescu C., Mulsant B., Rothschild A.J., Flint A.J., Meyers B., Whyte E. Pharmacotherapy of major depression with psychotic features: what is the evidence?. Psychiatric Annals 2006, 36(1):31-38.
3. Anton R.F., Burch E.A. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry 1990, 147:1203-1208.
4. Beck A.T., Kovacs M., Weissman M. Scale for suicide ideation. Journal of Consulting and Clinical Psychology 1979, 47:343.
5. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Patient Edition (SCID-I/P) 2001, Biometrics Research Department, New York.
6. Flint A.J. Psychopharmacological management of the medically ill older person. Geriatric Consultation Psychiatry 2001, 267-294. Oxford University Press, Oxford. P.S. Melding, B. Draper (Eds.).
7. Folstein M., Folstein S., McHugh P. "Mini mental state": a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12:189-198.
8. Guy W. ECDEU Assessment Manual for Psychopharmacology. Clinical Global Impressions 1976, 217-222. US Department of Health, Education, and Welfare, Washington, DC.
9. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960, 23:56-62.
10. Katon W., Russo J., Frank E., Barrett J., Williams J.W., Oxman T., Sullivan M., Cornell J. Predictors of nonresponse to treatment in primary care patients with dysthymia. General Hospital Psychiatry 2002, 24:20-27.
11. Kemmler G., Hummer M., Widschwendter C., Fleischhacker W.W. Dropout rates in placebo-controlled and active control clinical trials of antipsychotic drugs: a meta-analysis. Archives of General Psychiatry 2005, 62:1305-1312.
12. Labelle A., Boulay L.J., Lapierre Y.D. Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. Canadian Journal of Psychiatry 1999, 44:887-892.
13. Meyers B.S., English J., Gabriele M., Peasley-Miklus C., Moonseong H., Flint A.J., Mulsant B.H., Rothschild A.J. for the STOP-PD Study Group. A delusion assessment scale for psychotic major depression: reliability, validity, and utility. Biological Psychiatry 2006, 60:1336-1342.
14. Meyers B.S., Flint A.J., Rothschild A.J., Mulsant B.H., Whyte E., Peasley-Miklus C., Heo M., Papademetriou E., Leon A. for the STOP-PD Study Group. A double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression - the STOP-PD study. Archives of General Psychiatry 2009, 66:838-847.
15. Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H., Mulsant B.H., Reynolds C.F. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Research 1992, 41:237-248.
16. Oslin D.W., Datto C.J., Kallan M.J., Katz I.R., Edell W.S., TenHave T. Association between medical comorbidity and treatment outcomes in late-life depression. Journal of the American Geriatrics Society 2002, 50:823-828.
17. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 1962, 10:799-812.
18. Rothschild A.J. Challenges in the treatment of depression with psychotic features. Biological Psychiatry 2003, 53:680-690.
19. Rothschild A.J., Williamson D.J., Tohen M.F., Schatzberg A., Andersen S.W., Van Campen L.E., Sanger T.M., Tollefson G.D. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology 2004, 24:365-373.
20. Spiker D.G., Weiss J.C., Dealy R.S., Griffin S.J., Hanin I., Neil J.F., Perel J.M., Rossi A.J., Soloff P.H. The pharmacological treatment of delusional depression. American Journal of Psychiatry 1985, 142:430-436.
21. Spitzer R.L., Endicott J. Schedule for Affective Disorders and Schizophrenia (third edition) 1979, New York State Psychiatric Institute, Biometrics Research, New York.
22. Warden D., Trivedi M.H., Wisniewski S.R., Davis L., Nierenberg A.A., Gaynes B.N., Zisook S., Hollon S.D., Balasubramani G.K., Howland R., Fava M., Stewart J.W., Rush A.J. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. American Journal of Psychiatry 2007, 164:1189-1197.
23. Wijkstra J., Lijmer J., Balk F.J., Geddes J.R., Nolen W.A. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. British Journal of Psychiatry 2006, 188:410-415.
24. Wijkstra J., Burger H., van den Broek W.W., Birkenhäger T.K., Janzing J.G., Boks M.P., Bruijn J.A., van der Loos M.L., Breteler L.M., Ramaekers G.M., Verkes R.J., Nolen W.A. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavia 2010, 121:190-200.